- Home
- TVGN
as 07-26-2024 4:00pm EST
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes ("CD8+ CTLs" or "CTLs"), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | WARREN |
| Market Cap: | 132.9M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 218.3K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.74 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.65 - $21.09 | Next Earning Date: | 08-20-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Tevogen Bio Holdings Inc. Common Stock News
TVGN Breaking Stock News: Dive into TVGN Ticker-Specific Updates for Smart Investing
GlobeNewswire
15 days ago
Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback
GlobeNewswire
16 days ago
Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian
GlobeNewswire
18 days ago
Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social Responsibility
GlobeNewswire
a month ago
Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities
GlobeNewswire
a month ago
Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances
GlobeNewswire
a month ago
Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference
GlobeNewswire
a month ago
Tevogen Bio Set to Join Russell 3000® Index
GlobeNewswire
a month ago
Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
Compare TVGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TVGN Tevogen Bio Holdings Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.